Q3 FY25 Quarterly Investor Presentation & Webinar
Released
Released
Announcement PDF
ASX Announcement
30 April 2025
Q3 FY25 Quarterly Investor Presentation & Webinar
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to provide below its Q3 FY25 Investor
Presentation and Investor Webinar with CEO Dr Luke Reid presenting.
Quarterly Investor Presentation Webinar
Presenting: CEO, Dr Luke Reid
Webinar Access: The Quarterly Investor Presentation Video can now be accessed on demand via Microba’s Investor Hub at
the following link Q3 FY25 Quarterly Investor Video Presentation
Investor Q&As
We invite investors and interested parties to submit questions on the Quarterly Investor Presentation & Webinar through
the ‘Ask a question’ section of Microba’s interactive investor platform by following this link: Q3 FY25 Quarterly Investor Video
Presentation
This announcement has been authorised for release by the Board of Directors
For further information, please contact:
Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com
https://ir.microba.com/welcome
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology
for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for
major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.
Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the
microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com
JOIN MICROBA’S INTERACTIVE INVESTOR HUB
For more Company information and to engage with management by asking questions about Microba’s latest
announcements and updates, visit ir.microba.com/welcome
Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621
At the forefront of microbiome
diagnostics & therapeutics
Q3 FY25 Results
ASX: MAP
30 APRIL 2025
Authorised for release by the Board of Directors
Disclaimer
This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba).
Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any
obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in
evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act).
Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including
industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy.
Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.
Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is
not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you
should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.
Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been
prepared without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this
Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment
objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.
Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial
or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and
other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect",
"intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forwardlooking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking
statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of
Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results,
performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at
the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking
statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.
Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for
illustrative purposes only and is not represented as being indicative of Microba’s views on its future financial condition and/or performance.
Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in
this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.
Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or
damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency,
accuracy, reliability or completeness of this Presentation.
2
3
Q3 FY25 Results
Financial Highlights
Q3 Financial Highlights
4
Continued Growth & Clinical Adoption of Testing Products in Australia and UK
3225 MetaXplore tests sold AU (+201% vs PCP) | 246 MetaXplore tests sold UK (+1,018% vs PCP) | 212 MetaPanel tests sold (+1,827% vs PCP)
Continued Growth in Testing Volumes
4,000
+240%
Australia
•
Continued strong sales momentum for
MetaXplore with Q3 annualised run
rate of 12,900 MetaXplore tests sold,
up 201% vs PCP.
•
March MetaXplore sales was a record
month in Australia
•
MetaPanel market development
progressing with engaged KOLs and
landmark study results in IBD
3,500
3,000
2,500
2,000
1,500
United Kingdom
1,000
500
-
Q3FY24
MetaXplore (AUS)
Q4FY24
Q1FY25
MetaPanel (AUS)
Q2FY25
Q3FY25
MetaXplore (UK)
•
Migration from legacy testing products
to MetaXplore is going well
•
Strong month on month growth from
the early access program with Q3 test
sales of 246, and 99% MoM growth
from Feb-Mar
Evolution of UK Test Sales across CY2025
5
Positive migration of customers and sales to MetaXplore
39% of the total GI tests sales in the UK already replaced by MetaXplore
160
45%
140
40%
35%
MetaXplore Test Sales
120
30%
100
25%
80
20%
60
15%
40
10%
20
0
5%
Nov-24 Dec-24 Jan-25 Feb-25 March
MetaXplore
% Total GI Tests
0%
MetaXplore Test Sales as % of Total GI Tests
MetaXplore UK adoption
•
The migration of customers
over to MetaXplore is gathering
pace
•
Significant demand from
clinicians now waitlisted to
access MetaXplore
•
March MetaXplore sales
already representing 39% of the
total GI tests sales in the UK
•
Transition to MetaXplore
expected to complete by end of
CY2025
Evolution of Testing Product Revenue Mix
6
Executing sharp focus on key diagnostic testing products
Research - Divested
100%
Transferred to CMC in October 2024. Approx. $1m in
revenue has been recognised from October 2024 to Feb
2025. No further material revenue is forecast from March
2025 onwards.
90%
Testing Product Revenue as % of Total
80%
Insight – Migration to MetaXplore in Australia
Insight revenues in Australia ended Dec 2024, and
migrated to MetaXplore. International partner Insight
revenues to continue.
70%
60%
EcologiX~ – Migration to MetaXplore across 2025
Acquired in UK Invivo acquisition in Dec 2023. EcologiX
revenue in the UK expected to end by Dec 2025 and be
replaced by MetaXplore.
50%
40%
MetaPanel – Growth acceleration
Launched March 2024 in Australia in partnership with
Sonic Healthcare. Key revenue growth driver in Australia,
and in key international markets in the future.
30%
20%
MetaXplore – Growth acceleration
10%
0%
FY22
FY23
MetaXplore
FY24 ^
MetaPanel
H1FY25
1H
FY25
EcologiX
Insight
Q3FY25
Q3 FY25
Research
^ Invivo settlement took effect on 5 December 2023, ~ EcologiX includes whole Ecologic range + other distributed tests in the UK.
Launched March 2023 in Australia. Early access
commenced in UK in Oct 2024. Key revenue growth driver
in Australia and the United Kingdom, and in further key
international markets in the future.
Q3 Financial Highlights
7
Forecasting strong close to FY25, despite Q3 impact from strategic change in revenue mix
Annual Revenue Growth
$18,000,000
$16,000,000
+26% -34%
Quarterly Revenue & FY25 Q4 Guidance
$6,000,000
$10,000,000
Transitionary drop in Q3 revenue
aligned to changes in product and
revenue mix
•
Underlying Personal Testing &
Supplements business (core
diagnostic business) grew 3% vs
PCP, despite transitionary phase
•
Record March sales for both
MetaXplore and MetaPanel in
Australia
•
MetaXplore sales growing quickly
and moving to full market by end
of April FY25 in United Kingdom.
•
FY25 full year revenue guidance
of $15.25m-$16.25m representing
26% to 34% YoY growth
Total Revenue
-14%
$5,000,000
$14,000,000
$12,000,000
•
$4,000,000
$3,000,000
$8,000,000
$6,000,000
$2,000,000
$4,000,000
$1,000,000
$2,000,000
$0
Personal Testing
& Supplements
+3%
$-
Personal Testing & Supplements
Research Services
8
SECTION 3
Q3 FY25 Results
Business Highlights
Recent Milestones & Highlights
9
DIAGNOSTICS
THERAPEUTICS
1) Australia: Continued strong momentum in sales for
MetaXplore.
Transitioned from research and development
heavy phase to capital lite, sales and
partnering focused phase.
-
3,225 tests sold, up 201% vs PCP
698 ordering clinicians, up vs 130% PCP
Month on month record sales during the quarter
2) Australia: MetaPanel adoption continues to build.
-
212, tests sold, up 1,827% on PCP
Strategic agreement with major private Gastroenterology clinic
(~10k patients p.a.) to include MetaPanel into their clinical
protocols
3) United Kingdom: strong MoM growth in MetaXplore test sales
-
246 tests sold, up 1,018% on QoQ
98.6% MoM growth from Feb-Mar
MetaXplore tests represent 39% of GI tests sold in the UK
business as of 31 March
1 https://www.researchandmarkets.com/reports/5744225/probiotics-market-report?srsltid=AfmBOoq6GdcP9-S2QyrxXbUciO9F9ytAs9CsJURPUB2R7VpUJcPtsQUY
Two commercial streams to value return with
multiple opportunities being pursued:
1) Live biotherapeutics
Pharmaceutical product through FDA with
full Biological Licensure
1) Next-generation probiotics
Disrupting the $79B1 probiotic industry
with advanced new Medical Foods or
Dietary Supplement products
10
SUB-SECTION 3.1
DIAGNOSTICS RESULTS
Growing MetaXplore sales
and clinical adoption in Australia
MetaXplore Test Sales Volume (AU)
MetaXplore All Time Ordering Clinicians (AU)
4,392
1353
1045
3,225
11
•
Q3 – 3,225 tests sold, up 201% vs PCP
•
Q3 - 698 ordering clinicians, up 130%
vs PCP
•
Q3 annualised run-rate of 12,900
tests sold, up 201% vs PCP
•
Month on month record sales during
the quarter
•
Underpinned by growth in number of
ordering clinicians, whilst maintaining
the average order per clinician
2907
723
1782
436
Q1
955
181
H2FY23
H1FY24
H2FY24
Australia
H1FY25
Q3
FY25
Q3FY25
Q3 FY25
H2FY23 H1FY24 H2FY24 H1FY25 Q3FY25
Growing MetaPanel sales and clinical
adoption in Australia
MetaPanel Test Sales Volume (AU)
407
212
133
0
H1FY24
Australia
H2FY24
H1FY25
Q3
FY25
Q3FY25
12
•
Q3 sales of 212, up 1,827% on PCP
•
Landmark study results for IBD patients
•
3 new key opinion leaders engaged
•
Strategic agreement with major private
Gastroenterology clinic to include
MetaPanel into their clinical protocols
•
In market development phase. Expected to
take time to educate and develop target
clinicians before meaningful adoption and
sales
Landmark MetaPanel Study Results
•
MetaPanel test identifies
gastrointestinal pathogens in >35%
of Inflammatory Bowel Disease (IBD)
patients experiencing flare
•
•
>60% of these pathogens are missed
by current routine testing methods
These findings have the potential to
shift treatment protocols and
provide a new path to remission for
IBD patients, avoiding unnecessary
therapy escalation or surgery
Study 1
Two independent clinical studies
Flare
Remission
Study 2
•
13
Severe
flare
Positive MetaPanel
Associate Professor Graham Radford-Smith, one of Australia’s
leading expert in Inflammatory Bowel Disease
“These results are compelling, both as a clinical use case for MetaPanel, and for the
future of precision medicine in gastroenterology. For clinicians like myself managing
complex IBD cases, the ability to detect pathogens missed by routine testing could
transform how patients are treated.”
Partnership with Major Gastroenterology Clinic
•
Microba partnered with Colonoscopy Clinic and
Integrated Gut Health, one of Australia’s largest
private gastroenterology services which sees more
than 10,000 patients annually
•
The partnership aims to embed microbial
diagnostic testing into routine care to improve
patient outcomes
•
Key elements of the partnership include:
•
Routine use of MetaPanel and MetaXplore to
support diagnosis and treatment decisionmaking
•
Joint clinical research and publication efforts
to quantify the impact of Microba diagnostic
tests on patient outcomes
•
Development of a next-generation
gastroenterology care model centred on
Microba’s precision diagnostics
Associate Professor Dan Worthley,
Gastroenterologist at Colonoscopy Clinic
“We’re seeing an increasing number of patients with chronic and
complex gastrointestinal symptoms where standard testing and
colonoscopy isn’t giving us the full picture. Microba’s testing provides
a new lens into hidden pathogens, the microbiome and
gastrointestinal function which is delivering new outcomes for
patients..”
14
Growing MetaXplore sales
and clinical adoption in UK
MetaXplore Test Sales Volume (UK)
160
137
140
120
15
•
Q3 test sales for 246
•
98.6% MoM growth from Feb-Mar
•
MetaXplore tests represent 39% of GI
tests sold in the UK business as of 31
March
•
Aligned to strategy, the whole UK
testing business has transitioned to
focus on MetaXplore
•
Accelerating to full market access by
the end of June 2025.
100
80
69
60
40
Q1
40
20
0
9
Nov-24
13
Dec-24
Jan-25
United Kingdom
Feb-25
Mar-25
Robust Supplement sales &
revenue in United Kingdom
Supplement Revenue (UK)
Supplement Sales (UK)
35,000
$1,400,000
30,000
$1,200,000
25,000
$1,000,000
20,000
$800,000
15,000
$600,000
10,000
$400,000
Q1
5,000
$200,000
-
$-
Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25
United Kingdom
Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25
16
•
Supplement revenues remain robust
(+0.5% vs PCP)
•
30,029 supplements sold (-8.5% vs PCP)
•
Revenue increased vs PCP, supported by a
pricing uplift
•
Focused on:
•
Maintaining revenues whilst apply
focus on Diagnostics growth
•
Design of supplement growth
strategy
Advancing into the US
•
Entry strategy focused on 1 state, 1 metro area
•
USA represents >50% of global addressable market
($15bn of $25bn)
•
Cash pay entry aligned to existing markets
•
Demonstrate performant clinician adoption and patient
referral rates
•
Small sales and operational team
•
Leveraging Australia central lab
•
First hires expected before end of 2025
•
Reimbursement not required for entry, but progressing
as an accelerant to access
17
$25B+
* Assessment completed with Boston based MedTech specialist consultancy Veranex Inc. Assessment analysed US Medicare claims analysis for target patient populations, extrapolated Private and Medicaid numbers,
populations and prevalence adjusted for key global markets spanning outside of US including Germany, Italy, Spain, France, United Kingdom and Australia. Pricing predicates based on approved CPT coding, reimbursed
predicates, and other regional conservative pricing predicates.
18
SUB-SECTION 3.1
THERAPEUTICS
19
Transition to focus on partnering and revenue
• 5+ years of investment to develop a rich pipeline of live biotherapeutic
assets leveraging Microba’s world leading databank
• Deep preclinical and early clinical validation across key assets
• Focus is now on partnering to deliver these assets to patients and
provide a return on investment for shareholders
• There are two immediate commercial streams to value return:
1) Live biotherapeutics – Traditional drug route disrupting and
advancing standard of care
2) Next-generation probiotics – Disrupting the $79b probiotic market
with a step change advancement in product
• A small team, R&D lite, BD focused
19
20
Therapeutics
Transition to sales & partnering focus
Commercial strategy
Assets
Live Biotherapeutic Out license
Pharmaceutical drug (FDA – BLA)
MAP-315
IBD
•
Strategic partnerships
•
Non-dilutive equity investment
•
Non-dilutive grant-based funding
Market value potential
$1.5 - $11B
•
•
•
Upfront
Milestone payments
Royalties
Potential partner examples
MAP-XXX
Immuneoncology
Autoimmune
MAP-XXX
Next-Gen Probiotic Out license
Medical Food (FDA) or Dietary Supp (FTC&FDA - GRAS)
•
MAP-XXX
•
Structured pay to play product
development and commercialisation
programs
Non-dilutive federal and state grant-based
funding
$50 - $100M
•
•
Milestone payments
Royalties
Existing partner opportunity
• NYSE: IFF, $19.55B market cap
• Largest probiotic company in the world
• Just completed 1 year allergy discovery program
Other potential partner examples
20
21
SUB-SECTION 3.3
FOCUS & CATALYSTS
Key areas of focus & catalysts
Diagnostics
•
Australia – continued momentum in diagnostic
sales growth and clinical adoption
•
United Kingdom – accelerating MetaXplore to
full market access
•
United States – driving to first access and
reimbursement
Therapeutics
• LBP partnering & non-dilutive funding
• NGP partnering & non-dilutive funding
FY25 Revenue Guidance
• FY25 Revenue Guidance of A$15.25 - $16.25m
1 At 29 April 2025 | 2 At 31 December 2024
22
Financial Snapshot
ASX Code
MAP
Market capitalisation1
$100m
Shares on issue
447.85m
52-week low / high1
Cash Balance (31 March 2025)
$0.145 / $0.325
$12.4m
Major Shareholders
Shareholder
Ownership %2
Sonic Healthcare
19.14%
Perennial
14.99%
SA Microba Holdings
7.48%
Thorney Investment Group
6.69%
Macrogen
3.98%
Philip Hugenholtz
3.84%
Gene Tyson
3.82%
23
SECTION 4
Microba Overview
Whole Business Recap
24
SUB-SECTION 4.1
COMPANY SNAPSHOT
Unequivocal evidence demonstrates that the human gut
microbiome is a critical component of disease
>21,000 Research publications
demonstrate a clear link between chronic
diseases and the gut microbiome1
1 PubMed search terms "gut microbiome/microbiota" or "stool microbiome/microbiota" or "faecal microbiome/microbiota" and "disease"
25
Changing the microbiome can change disease outcomes
>150
Global clinical studies demonstrate that microbiome modulation
can influence disease outcomes and clinical symptoms1
Infectious Disease
Inflammatory Disease
Autoimmune Disease
Cancer
Mental Health
Metabolic Disorders
Heart Disease
Neurodegenerative Disease
1 PubMed search terms "gut microbiome" and "modulate" and "clinical study" and manually selecting for clinical trials with positive results indicated in the abstracts.
26
Combating chronic disease through microbiome
diagnostics and therapeutics
$1.4 trillion healthcare disruption opportunity
Microbiome testing to diagnose and match patients
with the right treatment
Microbiome therapy to treat
chronic diseases
$125B Est. TAM
$1.3T Est. TAM
Management estimate based on desktop study of the total number of patients across the top 10 chronic diseases impacted by the microbiome, across the United States,
United Kingdom, Australia, France, Germany, Spain & Italy. Conservative diagnostic and therapeutic pricing in USD applied based on existing predicates.
27
28
“Our partnership with Microba exemplifies our commitment to invest
in cutting edge developments in laboratory medicine. We see microbiome testing
becoming a key part of pathology over coming years and are excited about the
potential of this partnership and the opportunities that Microba's technology will
provide for Sonic’s global operations, our referring clinicians and our patients.”
Dr Colin Goldschmidt – CEO, Sonic Healthcare
29
SUB-SECTION 4.2
DIAGNOSTICS
30
Our diagnostics vision:
To combat disease through microbiome health
31
Our diagnostics focus
Patients suffering from gastrointestinal disease
→
Gastrointestinal
Mental
Cardiovascular
Oncology
Longevity
Fertility
Gastrointestinal Disease
Half of patients are not getting a resolution
37,310,000
Patients presenting annually in the US
with lower GI abdominal symptoms*
21,500,000
Pain, bloating, other
15,370,000
53%
Resolved
32
47%
Unresolved
Diarrhoea
440,000
IBD
% of patients achieving resolution of gastrointestinal
symptoms after 5 years**
* Assessment of Medicare claims analysis. Estimated Private and Medicaid numbers extrapolated from Medicare claims analysis completed with Boston based MedTech specialist consultancy Veranex Inc.
** Gordon, J., Miller, G., & Valenti, L. (2015). The management of unresolved gastrointestinal symptoms in Australian general practice. Australian Family Physician, 44(9), 621-623
Addressing the GI symptom challenge
Microba’s comprehensive diagnostic products
First line
Diagnosing
pathogenic causes
of GI symptoms
Gastrointestinal pathogen test
Launched March 2024
Stool DNA test.
175 targets.
Expertly curated clinical recommendations for targeted treatment.
Second line
Identifying functional
causes and treatment
options for
non-pathogenic
GI symptoms
Gastrointestinal disorder test
Launched February 2023
Stool DNA + targeted biomarker test.
7 functional GI markers. >28k microbiome markers.
Expertly curated clinical recommendations for personalised treatment.
33
Getting answers for patients in need
Closing the gap on GI symptom diagnosis and treatment
100%
47%
28% new insights with
*
50%
**
24% new diagnoses with
Unresolved
**
0%
% of patients achieving resolution of
gastrointestinal symptoms after 5 years
52% receiving critical new diagnoses and treatment
recommendation for these patients.
* Study of first 17 months of MetaXplore test results in clinical practice in Australia
** Study of first 4 months of MetaPanel test results in clinical practice in Australia
34
A multi-billion dollar market opportunity
$25B+
Total Market Size*
* Assessment completed with Boston based MedTech specialist consultancy Veranex Inc. Assessment analysed US Medicare claims analysis for target patient populations, extrapolated Private and Medicaid
numbers, populations and prevalence adjusted for key global markets spanning outside of US including Germany, Italy, Spain, France, United Kingdom and Australia. Pricing predicates based on approved
CPT coding, reimbursed predicates, and other regional conservative pricing predicates.
35
Transforming standard of care
A paradigm shift
36
“After the first 4 months using the
MetaPanel test, 24% of patients have
been diagnosed with a pathogen that
would have been undiagnosed or
experienced delayed time to diagnosis
and resolution.
This is a breakthrough in infectious
disease management”
Dr Michael Wehrhahn
BSc (Med) MBBS (Hons) MPH (Hons) FRACP FRCPA
Clinical Microbiologist,
Infectious Disease Physician & Director
of Molecular Biology
Changing lives every day
“Before completing the MetaXplore test with my practitioner, my health was in
constant distress. I looked and felt bloated all the time, to the point of appearing six
months pregnant. My severe constipation led to bowel movements only every 5-6
days with trapped gas causing extreme pain. After completing the MetaXplore test
and implementing my treatment plan, I have experienced remarkable improvements.
My bowel movements are now regular, averaging every 2-3 days. The trapped gas
and extreme pain are gone, significantly improving my daily life. With adherence
to the treatment plan, I no longer suffer from bloating, pain, reflux, or indigestion”
37
MetaXplore
patient
Changing lives every day
“I have struggled with gastrointestinal symptoms for over half my life. I have
tried resolving with many specialists, restrictive eating plans and natural
therapies. My MetaXplore test this year identified clear problems and a
personalised treatment plan. I am grateful that through following the
treatment plan I have achieved complete resolution to my symptoms and
can enjoy eating unrestricted for the first time in 35 years.”
38
MetaXplore
patient
39
SUB-SECTION 4.3
THERAPEUTICS
40
Our Therapeutics Vision
To combat disease through microbiome health
40
41
Our primary therapeutic focus
Clinical: Patients suffering from Inflammatory Bowel Disease
Autoimmune
Oncology
Allergy
Neuro
Cardiovascular
→
Gastrointestinal
41
42
Microba is Pioneering an Advanced AI/ML Approach
For the Development of Next Generation Precision Live Biotherapeutics
Target Prediction
Disease Relevant Activity
Disease
Prevalence
Donor
Isolation
Human Data
Driven
Precision
Microbiome
Therapeutics
AI & Machine
Learning
Health Data
Biome Data
Species
Identification
>60,000 metagenomes*
>1,000 health indicators/participant
>1M Genomes
>100M Genes
>100K species
*Derived from both internal and external data
In Silico Analysis
Supportive
Bioactivity
>100TB of DNA data
8,000B alignments
200M CPU hours processing time
20K vCPUs, 50TB RAM
>9,000 isolated strains
>500 species isolated in total
>200 previously uncultured species isolated
1 Phase II ready asset
Multiple pre-clinical leads
42
43
Therapeutic pipeline & catalysts
Core Program
IBD
(Ulcerative colitis)
Discovery R&D
Phase 1
MAP 315
(LBP)
Phase 2
Development
Partners
Phase 2 IND
submission currently
being compiled
Undisclosed
(LBP)
Immuno-oncology
Undisclosed
(LBP)
Autoimmune
Undisclosed
(LBP)
LBP = Live Biotherapeutic Product
Preclinical
Pre-clinical biology
supporting lead
candidate selection
Laboratory & animal model
experiments confirming
activity
43
44
Therapeutics
Transition to sales & partnering focus
Commercial strategy
Assets
Live Biotherapeutic Out license
Pharmaceu
Share your feedback
Discover